SCHEMBL215330

SCHEMBL215330

Cc1ccc(Br)cc1-n1cnc(C(N)=O)c1C(=O)Nc1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 1/20 0.46
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
GRM4 Q14833 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSPD1 P10809 1/20 0.42
HSPE1 P61604 1/20 0.42
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213700 0.90 SORT1 (0.46) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL215228 0.89 SCN9A (0.44) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL214574 0.87 RAB9A (0.41) ALDH1A1MAPTMEN1KMT2AGRM4
SCHEMBL215824 0.87 RAB9A (0.41) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL214245 0.85 NPC1 (0.41) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL213975 0.85 KMT2A (0.42) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL214745 0.82 KMT2A (0.41) ALDH1A1MAPTMEN1KMT2ARAB9A
SCHEMBL215407 0.80 MTOR (0.38) HPGDMEN1KMT2AKDM4ERAB9A
SCHEMBL214926 0.79 RAB9A (0.37) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL214864 0.79 JAK2 (0.32) MEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 ALDH1A1 4295/4885MAPT 2138/4885HPGD 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.